A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors

Trial Profile

A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs EC 1456 (Primary) ; Technetium Tc99m etarfolatide (Primary)
  • Indications Advanced breast cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Endocyte
  • Most Recent Events

    • 02 Apr 2018 Planned End Date changed from 1 Jan 2018 to 30 Jan 2018.
    • 06 Jun 2017 Results (n=74) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 According to an Endocyte media release, the company is stopping enrollment in the phase Ib part of this trial because assessment in folate receptor-positive (FR-positive) disease across multiple cohorts of patients and multiple dosing schedules did not yield the level of clinical activity necessary to support continued advancement of this agent.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top